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OBJECTIVES This study compares the long-term performance of the Carpentier-Edwards (CE) porcine
bioprosthesis and the CE pericardial bioprosthesis for aortic valve replacement (AVR).
BACKGROUND With new bioprostheses on the horizon, there is renewed interest in how the long-term
durability of current pericardial bioprostheses compares with the traditional porcine biopros-
thesis.
METHODS We reviewed 518 AVR with CE porcine valves from 1974 to 1996 and 1,021 AVR with CE
pericardial valves from 1991 to 2002. The age distribution and clinical profiles were similar
for both groups. The total (mean) follow-up was 3,322 (6.4) years for porcine and 2,556 (2.5)
years for pericardial.
RESULTS Long-term mortality was similar (p  0.29) for porcine and pericardial, with 10-year survival
rates of 34  2% and 38  6%, respectively. Ten-year freedom from major adverse cardiac
events was also similar for both (respectively): thromboembolism (80  2% and 87  2%; p
 0.24); endocarditis (98  1% and 99  1%; p  0.30). However, 10-year freedom from
explant was lower for porcine (90  2%) than for pericardial (97  1%, p  0.04). Reasons
for explant for porcine were structural valve deterioration (SVD) (n  25), endocarditis (n 
4), and periprosthetic leak (n  2). The reasons for explant for pericardial were SVD (n 
4), endocarditis (n  4) and periprosthetic leak (n  1).
CONCLUSIONS The current CE pericardial valve offers better midterm durability than the traditional CE
porcine valve. Its freedom from SVD and reoperation makes it our current bioprosthesis of
choice for AVR in appropriately selected patients. (J Am Coll Cardiol 2004;44:384–8)
© 2004 by the American College of Cardiology Foundationp
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hhe first generation of pericardial valve prostheses was aban-
oned by physicians owing to a high rate of structural valve
eterioration (SVD) characterized by leaflet tear (1–3). The
arpentier-Edwards (CE) pericardial valve was introduced in
981 and became available for commercial distribution in the
.S. in 1991, providing superior hemodynamic performance
ith better durability than its previous pericardial valves.
ntermediate follow-up has shown a low rate of valve-related
See page 389
vents, especially deterioration. This satisfactory outcome re-
abilitated pericardium as a viable bioprosthetic valve substi-
ute (4,5). However, because of the history of other biopros-
heses and the known evolution of calcification of these
aterials over time, longer follow-up is necessary to assert a
efinitive conclusion. More than 10 years have passed since the
E pericardial valve was approved by the Food and Drug
dministration (FDA) for aortic valve replacement (AVR).
his study documents our center’s experience with the CE
ericardial valve implanted in the aortic position and compares
t to that of CE porcine valve.
ATIENTS AND METHODS
e reviewed all 518 isolated AVR performed with CE
orcine valves between 1974 and 1996 and all 1,021 AVR
From the Providence Health System, Portland, Oregon.
Manuscript received August 22, 2003; revised manuscript received December 30,t003, accepted January 27, 2004.erformed with CE pericardial valves between 1991 and
002. Table 1 summarizes the preoperative clinical profiles
f each group. Mean age was 74 years for both porcine
roup (range 23 to 95 years) and pericardial group (range 26
o 94 years). Not only are the mean ages identical, but the
ntire age distributions of the two valves are similar as well
Fig. 1). Patients who underwent combined valve replace-
ent were excluded from this study. Patients with signifi-
ant coronary artery disease receiving preoperative angiog-
aphy underwent concomitant coronary artery bypass graft
urgery and are included in this study.
All patients were entered into a database at the time of
he operation and have been followed up prospectively at
nnual intervals; the recent follow-up was conducted by
ither mailed questionnaire or telephone interview. The
otal (mean) follow-up was 3,322 (6.4) years for the porcine
roup and 2,556 (2.5) years for the pericardial group.
ollow-up was 91% complete.
All valve-related deaths and complications were defined
ccording to the “ Guidelines for Reporting Morbidity and
ortality After Cardiac Valvular Operations” (6). The
rimary outcome of interest in this analysis was biopros-
hetic valve dysfunction. This was defined as any clinically
elevant valvular stenosis or insufficiency documented by
eoperation or autopsy. Additional outcomes included
hromboembolic events, bioprosthetic valve endocarditis,
nd cause of death. Cause of death was established from
ospital records or autopsy reports when available. Opera-
ive death and early thromboembolism were defined as any
d
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July 21, 2004:384–8 Pericardial Versus Porcine Aortic Valveseath and any thromboembolism in the hospital or within
0 days after operation.
tatistical analyses. Continuous data are presented as
ean  SD and actuarial probability and linearized rates as
ean and 95% confidence limits of the mean. Linearized
ates are the number of events per patient-year (%/patient-
ear) of follow-up. Survival curves and event-free curves
ere obtained using Kaplan-Meier (KM) method and
ompared by log-rank test. Actual analysis was also done to
et the actual event-free percentage for SVD. Cox regres-
ion was used to detect the risk factors for SVD and
xplantation. Only the first event for each patient during the
tudy was used for event-free analysis. Valve-related com-
lications except for SVD were summarized as linearized
ates, and all late events for each patient were included. The
tatistical analysis was done by SPSS 10 (SPSS Inc.,
hicago, Illinois) and S-PLUS 2000 (Insightful Corp.,
eattle, Washington). Although the maximum follow-up of
he porcine valves exceeds that of the pericardial valves by
bout eight years, the log-rank test used for statistical
omparison considers the experience for both valves only out
o the follow-up time of the shortest series.
ESULTS
perative and late deaths. There were 40 operative deaths
7.7%) in the porcine group and 43 (4.2%) in the pericardial
roup. There were 327 late deaths in the porcine group and
Abbreviations and Acronyms
AVR  aortic valve replacement
CE  Carpentier-Edwards
FDA  Food and Drug Administration
KM  Kaplan-Meier
SVD  structural valve deterioration
able 1. Clinical Profiles of Patients
Porcine Pericardial
o. of valves 518 1021
ge (yrs) 74 (23–95) 74 (26–94)
ender (M/F) 320/198 606/415
OPD 22 (4%) 171 (17%)
ypertension 5 (1%) 57 (6%)
ulmonary hypertension 27 (5%) 96 (9%)
enal failure 5 (1%) 57 (6%)
eripheral vascular disease 65 (13%) 126 (12%)
istory of CABG 17 (3%) 91 (9%)
alve size
19 41(4%)
21 134 (26%) 225 (22%)
23 210 (41%) 376 (37%)
25 125 (24%) 245 (24%)
27 46 (9%) 105 (10%)
29 3 (0.6%) 27 (3%)
PB time, min (mean  SD) 76  68 120  47
ssociated CABG 210 (41%) 507 (50%)
ABG  coronary artery bypass graft; COPD  chronic obstructive pulmonary
isease; CPB  cardiopulmonary bypass.64 late deaths in the pericardial group. A summary of the
auses of late death in both groups is shown in Table 2.
mong the late deaths in the porcine group, 37% were
alve-related, 25% were non-valve-related, and 38% were
oncardiac related. Among the pericardial group, 41% were
alve-related, 15% non-valve-related, and 44% were non-
ardiac related. Overall long-term mortality was similar (p
0.29) for the porcine and pericardial, with 10-year
urvival of 34  2% and 38  6%, respectively (Fig. 2).
rosthetic valve thrombosis. There was one early and one
ate thrombosis of the porcine valve (0.03%/patient-year).
here were no documented thromboses of the pericardial
alves.
hromboembolic events. Eight (1.5%) early thromboem-
olic events occurred in the porcine group and 26 (2.6%) in
he pericardial group. Eighty-six late thromboembolic
vents (2.6%/patient-year) occurred in the porcine group: 3
eripheral, 20 transient ischemic attack, 3 reversible isch-
mic neurologic deficit, 39 stroke, and 21 fatal. Thirty-one
ate thromboembolic events (1.3%/patient-year) occurred in
he pericardial group: 3 transient ischemic attack, 16 stroke,
nd 12 fatal. Ten-year freedom from thromboembolism was
imilar for the porcine and pericardial (80  2% and 87 
%, respectively; p  0.24) (Fig. 3).
igure 1. Age distribution of patients undergoing aortic valve replacement
ith porcine and pericardial valve (vertical axis represents percentage).
able 2. Causes of Late Death
Cause Porcine Pericardial
ardiac 203 (62%) 91 (56%)
Valve related 122 (37%) 67 (41%)
Thromboembolism 20 (6%) 11 (7%)
Hemorrhage 1 (0.4%) 3 (2%)
Endocarditis 2 (0.6%) 1 (0.6%)
Valve thrombosis 1 (0.4%) 0
Periprosthetic leak 2 (0.6%) 0
Sudden death/unknown 96 (29%) 52 (32%)
Non–valve-related 81 (25%) 24 (15%)
oncardiac 124 (38%) 73 (44%)
otal 327 164
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Pericardial Versus Porcine Aortic Valves July 21, 2004:384–8ioprosthetic valve endocarditis. There were 1 early and
0 late episodes of prosthetic valve endocarditis in the
orcine group (0.3%/patient-year). There were two early
nd four late episodes of prosthetic endocarditis in the
ericardial group (0.16%/patient-year). Ten-year freedom
rom endocarditis was similar for the porcine and pericardial
98  1% and 99  1%, respectively; p  0.30).
eoperation. The 10-year KM freedom from explant was
igher for the pericardial group (97  1%) than for the
orcine (90  2%, p  0.04) (Fig. 4). Causes of explant for
orcine were SVD (n  25), endocarditis (n  4), and
eriprosthetic leak (n  2). The causes of explant for
ericardial were SVD (n  4), endocarditis (n  4), and
eriprosthetic leak (n  1). The 10-year KM freedom from
xplantation for SVD was 92  2% in the porcine group
nd 98.5  1% in the pericardial group (Fig. 5). The
0-year actual freedom from explantation for SVD was 96
1% for the porcine and 98.9  1% for the pericardial.
he 15-year KM and actual freedom from explantation for
VD was 87  1% and 95 1% in the porcine group,
espectively. By Cox regression, only younger age was found
igure 2. Probability of survival for porcine and pericardial aortic valve
eplacement patients.
igure 3. Freedom from thromboembolic events for porcine and pericar-
ial aortic valve replacement patients. ao be a significant risk factor for SVD. The SVD rate
ecreased with older age in the porcine group (Fig. 6). In
he pericardial group, four cases of SVD occurred: one in a
atient under 50 years old and three in patients more than
0 years old.
ISCUSSION
he rationale for using bioprosthetic valves is their low
hrombogenicity, which does not require anticoagulation
er se. Therefore, these valves seem to be eminently suitable
or patients with isolated aortic valve disease, who are in
inus rhythm and do not usually have any concomitant
ardiomyopathy that would necessitate anticoagulation.
For the past 30 years stented porcine valves have been the
ost widely used biologic valves, and they represent a
tandard for measuring the performance of newer biologic
alve designs. The first-generation pericardial bioprostheses
ffered improved hemodynamic performance over the por-
ine valves, but were plagued by early structural failure and
ere finally withdrawn from the market (1–3). In contrast,
igure 4. Freedom from explant for porcine and pericardial aortic valve
eplacement patients.
igure 5. Freedom from structural valve deterioration (SVD) for porcine
nd pericardial aortic valve replacement patients.
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July 21, 2004:384–8 Pericardial Versus Porcine Aortic Valveshe original design of the CE pericardial valve offers
xcellent intermediate and long-term follow-up results and
as demonstrated that pericardium is in fact an acceptable
ioprosthetic material. Pericardium’s superior durability is
ue to decreased stress-induced structural deterioration
hrough infrastent tissue-mounting, flexible and distendable
truts, and better tissue orientation combined with im-
roved tissue preservation techniques (7). There has been
ncreasing interest in the CE pericardial valve since it gained
DA approval for aortic implantation in the U.S. in 1991.
linical outcomes of valve replacement with the CE peri-
ardial valve have been previously reported by other groups
8–11). We present our experience with this prosthesis,
tarting from the FDA approval in 1991, and compare it
ith our results with the CE porcine valve.
Our patients were operated on by the same surgical team.
here was similarity between the two groups in preoperative
linical profile, including age distribution, clinical status,
nd associated surgical procedures. The limitation of this
tudy is that the comparison between the porcine and
ericardial valve is not contemporaneous. The reason is that
ince the pericardial valve became available in the U.S. we
ave switched almost entirely to the pericardial valve. With
ore than 1,000 pericardial valves implanted in aortic
osition and up to 10 years follow-up, we felt it was time to
nalyze our comparative long-term results.
For the CE pericardial group, overall late survival rates
nd freedom from valve-related complications, including
hromboembolic events and endocarditis, paralleled those
bserved for the porcine group. But freedom from explant
as better for the pericardial than for the porcine. This
eems to be due to a lower rate of SVD, as only four
ericardial valves have been explanted because of SVD.
Age and valve position have been shown to be the most
owerful determinants of bioprosthetic valve longevity, with
ncreasing durability in the aortic position of elderly patients
8,12–15). In our series, the influence of age on porcine
igure 6. Freedom from structural valve deterioration (SVD) for porcine
ortic valve replacement patients in different age groups.alve structural deterioration was significant. There ap- aeared to be a decrease in structural deterioration with
ncreasing age in porcine series. However, the pericardial
alve structural deterioration had too few occurrences to
llow us to find a relationship with age. Similar results have
een reported for the CE pericardial valve in the aortic
osition by Cosgrove et al. (4). They concluded that age was
ot a significant predictor of the explantation of the pros-
hesis because after 10 years 97% of patients 65 years and
lder and 94% of those under 65 years were free from
tructural deterioration.
Jamieson et al. (16), on the other hand, reported that the
E porcine valve had significantly greater freedom from
tructural failure at 15 years in patients 70 years and older.
anbury et al. (17) reported actuarial freedom from aortic
E pericardial valve SVD of 99%, 94%, and 77% at 5, 10,
nd 15 years, respectively. They found that the long-term
urability of the pericardial valve is excellent, particularly in
he elderly. In that series patients as young as 65 years were
redicted to have 10% chance of requiring explant before
he age of 80. These results are very encouraging. As these
tudies mature, indications for CE pericardial use may
roaden to include a younger population.
Comparison between porcine and pericardial valves was
reviously reported (18,19). Cosgrove et al. (18) showed
hat pericardial valves are less obstructive than porcine. New
ericardial valves appear to compare favorably with the best
ublished results of studies on the first-generation porcine
rostheses (20,21). The 10-year freedom from structural
ailure ranges from 76% to 91%. The Carpentier group has
bserved freedom from structural deterioration rates of
00% at 12 years and 83% at 13 years.
We have compared our earlier experience with porcine
alves (1974 to 1996) with our later experience with pericardial
alves (1991 to 2002). These were the first-generation porcine
alves, compared with the second-generation pericardial valves.
ecause we have adopted pericardial as our preferred valve, we
o not have experience with more recent porcine valves. The
econd-generation porcine valve (Carpentier-Edwards SAV
orcine, Edwards Lifesciences, Irvine, California; Hancock II,
edtronic Inc., Minneapolis, Minnesota) and third-
eneration Mosaic Porcine Valve (Medtronic Inc.) were de-
igned as supraannular bioprotheses to reduce the obstructive
roperties of the first-generation standard intra-annular por-
ine bioprostheses (22). Recent study by Jamieson et al. (23)
evealed no difference among the Carpentier-Edwards SAV
orcine, Medtronic Mosaic porcine, and CE pericardial bio-
rostheses with regard to mean gradients by prosthesis size or
ndexed effective orifice area by prosthesis size. Jamieson et al.
24) reported that 15-year freedom from SVD with second-
eneration CE porcine valve was 69% for patients age 61 to 70
ears and 92% for those older than 70 years, respectively. This
esult is similar to that of our porcine series. Corbineau et al.
25), in reviewing 13-year results with Medtronic Intact
orcine bioprosthesis in the aortic position, reported that
reedom from SVD at 10 and 13 years was respectively 96%
nd 91%, which seems better than our CE porcine series but
n
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Pericardial Versus Porcine Aortic Valves July 21, 2004:384–8ot as good as our CE pericardial series. It remains to be seen
hether these newer generations of porcine valves will equal or
xceed the results with pericardial valves. Nonetheless, the rates
f explantation of pericardial AVR in our series and others
trongly suggest that the traditionally purported risk of a “50%
hance of reoperation at 10 years” with porcine bioprostheses is
o longer valid. Indeed, we as clinicians must reevaluate and
eeducate our peers and patients on the true risks and benefits
f AVR utilizing current bioprosthetic valve technology.
In summary, compared with the CE porcine valve, the
E pericardial valve has superior durability. Its freedom
rom structural deterioration and reoperation makes it our
ioprosthesis of choice for aortic valve replacement. The
0-year results for the pericardial valve continue to demon-
trate a strong performance, which may broaden its indica-
ion to younger patients with aortic valve disease.
eprint requests and correspondence: Dr. YingXing Wu, 9205
W Barnes Road, #33LL, Portland, Oregon 97225. E-mail:
ingXing.Wu@providence.org.
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